Yahoo Finance

Eisbach Bio Announces First Patient Dosed in Phase 1/2 Trial for EIS-12656, a First-In-Class Allosteric Inhibitor of ALC1 in Refractory Advanced Solid Tumors

MARTINSRIED, Germany, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Eisbach Bio GmbH (“Eisbach” or the “Company”), a privately-held clinical-stage biotechnology company pioneering cancer medicines leveraging ...
Yahoo Finance

Eisbach Bio positions HRD-targeting therapy to supplant PARP inhibitors

Eisbach Bio plans to use a $4.75m grant to advance EIS-12656, a small molecule ALC1 inhibitor to disrupt the genome structure in hard-to-treat cancer cells, says CEO Dr. Adrian Schomburg. Last month, ...
PharmiWeb

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors Eisbach Is Enabling the Potential of ...
Yahoo Finance

Eisbach Bio Receives EUR 8 Million Government Grant to Progress COVID-19 Antiviral Through Phase I/II Clinical Development

MUNICH, Germany, July 7, 2021 – Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease, today announced additional financial support from the German Ministry ...
ksn.com

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors

MARTINSRIED, Germany and HOUSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Eisbach Bio GmbH (Eisbach), a clinical-stage biotechnology company pioneering a new class of cancer medicines leveraging synthetic ...